Home > Back to Publisher > Report Information

Regenerative Medicines: Bone and Joint Applications

BCC Research
October 1, 2009
290 Pages - SKU: WA2493289

Abstract Table of Contents Related Reports

REPORT HIGHLIGHTS

Overall sales in the regenerative medicine productsmarket were worth $1.1 billion in 2007, and remained flat into 2009. By 2014, sales are projected to increase to nearly $1.8 billion, for a 5-year compound annual growth rate (CAGR) of 8.6%.
The largest segment in the market, bone replacement/grafting, was valued at $714 million in 2007. This also has increased only slightly into 2009 but is projected to reach $979 million in 2014, for a 5-year CAGR of 6.3%.
Sales in the bone growth stimulators product segment were worth $321 million in 2007, and were to increase slightly into 2009. By 2014, however, they are projected to increase to $578 million, for a 5-year CAGR of 11.9%.

CHAPTER ONE: INTRODUCTION: OBJECTIVES AND GOALS OF STUDY; INTENDED AUDIENCE; SCOPE OF REPORT; METHODOLOGY; INFORMATION SOURCES; ANALYST CREDENTIALS; RELATED BCC REPORTS; BCC ONLINE SERVICES; DISCLAIMER
CHAPTER TWO: SUMMARY
CHAPTER THREE: OVERVIEW AND OVERALL STATUS OF THE INDUSTRY: TOTAL SCOPE OF REGENERATIVE MEDICINE MARKET; HOW REGENERATIVE MEDICINE WORKS; TISSUES AND ORGANS ON DEMAND; ORGAN REPLACEMENT IS A $100 BILLION PER YEAR BUSINESS; EXAMPLES OF IMPACT ON EXISTING CONDITIONS AND DISEASES; BARRIERS TO REGENERATIVE MEDICINE; CURRENT R&D PRIORITIES; TOTAL OUTPUT OF THE SECTOR; REGENERATIVE MEDICINE AND HEALTHCARE ECONOMICS; POPULATION TRENDS; MARKET TIMING; OVERSEAS INITIATIVES
CHAPTER FOUR: PRINCIPLE APPROACHES TO REGENERATIVE MEDICINE: PRINCIPLE APPROACHES TO REGENERATIVE MEDICINE; HUMAN SUBSTANCES; CELLS AND TISSUES; TISSUE ENGINEERING; Importance of Scaffolding in Tissue Engineering; Blood Vessel Scaffolding; Center for Integration of Medicine and Innovative Technology (CIMIT); Massachusetts General Hospital; Duke University Stem Cell and Regenerative Medicine Program; EMBRYONIC STEM CELLS; THERAPEUTIC CLONING; ADULT STEM CELLS: JUST AS GOOD AS EMBRYONIC STEM CELLS; GENZYME; UNIVERSITY OF MINNESOTA STEM CELL INSTITUTE; STEM CELL RESEARCH PATENTS AND EFFECT ON STEM CELL MARKETERS; SETTING THE STAGE FOR REGENERATIVE MEDICINE TO TREAT BONE AND JOINT DISORDERS; NOVEL MATERIALS; GENE THERAPY; Gene Therapy Trials Targeting Bone and Joint Diseases and Disorders; BIOREACTOR USE IN REGENERATIVE MEDICINE; THE IMPACT OF GENOMICS
CHAPTER FIVE: PRODUCTS AND TECHNOLOGIES: CATEGORIES OF REGENERATIVE MEDICINE: GENE- AND PROTEIN-BASED APPROACHES; ANTIBODIES; The Importance of Antibody Drugs; Advantages of Monoclonal Antibody Drugs; Antibodies and Osteoarthritis; GROWTH FACTORS; HOW BMPS FUNCTION; Clinical Uses; Companies; CELLS AND TISSUES; TISSUE ENGINEERING; ARTIFICIAL SKIN; CARTILAGE; OTHER APPROACHES TO CARTILAGE; BIOSYNTHETIC COMPOSITES FOR CARTILAGE REPAIR; THE MARKET FOR TISSUE-ENGINEERED CARTILAGE PRODUCTS; OTHER PRODUCTS; CREATION OF ENTIRE ORGANS; EMBRYONIC STEM CELLS; NOVEL MATERIALS AND BIOMATERIALS
CHAPTER SIX: STEM CELL THERAPIES AND REGENERATIVE MEDICINE: STEM CELLS AS POTENTIAL REPLACEMENT CELLS; TECHNICAL IMPEDIMENTS; OVERVIEW OF FUNDING; STATE-LEVEL INITIATIVES FOR STEM CELL RESEARCH; POTENTIAL APPLICATIONS: CURRENT STATUS; IN VIVO REPROGRAMMING; UMBILICAL CORD BLOOD STEM CELLS; Recent Research Developments; INDUCED PLURIPOTENT STEM CELLS; Recent Research Developments; Adult Multipotent Stem Cells; Embryonic Stem Cells; GERON AND THE FIRST HUMAN TRIALS; OTHER STEM CELL RESEARCH; STATUS OF OTHER CLINICAL TRIALS; STEM CELL THERAPY FOR ALS; STEM CELL THERAPY FOR DUCHENNE MUSCULAR DYSTROPHY; STEM CELL THERAPY AND BONE MARROW TRANSPLANTS
CHAPTER SEVEN: REGENERATIVE PRODUCTS TO TREAT BONE DISEASES: REGENERATIVE PRODUCTS TO TREAT BONE DISEASES; OSTEOBIOLOGICS; BONE GRAFTS; AUTOGRAFTS; BIOSEED GRAFTS; ALLOGRAFTS; DEMINERALIZED BONE MATRIX PRODUCTS; Accell; AlphaGRAFT; Allomatrix; Grafton DBM; DBX; DynaBlast and DynaGraft-D; Graftech; Grafton; Opteform; OrthoBlast II; Osteofil; Solo Cervical Allograft; XENOGRAFTS; THE MARKET FOR ALLOGRAFTS; CELL-BASED BONE GRAFT SUBSTITUTES; FACTOR-BASED BONE GRAFT SUBSTITUTES; BONE MORPHOGENIC PROTEINS; INDUCTOS; INFUSE BONE GRAFT; OP-1 IMPLANT; CERAMIC-BASED BONE GRAFT SUBSTITUTES; TYPES OF CERAMICS; Alpha-BSM; BioGran; Bio-Oss; BoneSource; Calcigen S; Collagraft Strip Bone Graft Matrix; Conduit TCP Granules; IsoTis Products; Mimix Bone Substitute Material; Norian SRS; OsteoGraf; Osteoset; OsteoStim Resorbable Bone Graft Substitute; PerioGlas; Pro Osteon Implant; Vitoss; POLYMER-BASED BONE GRAFT SUBSTITUTES; CORTOSS; HEALOS; IMMIX EXTENDERS AND IMMIX CB; THE MARKET FOR BONE GRAFT PRODUCTS; REGENERATIVE MEDICINE PRODUCTS IN DEVELOPMENT FOR BONE APPLICATIONS; BIOLOGIC/SYNTHETIC GRAFTS; CHRYSALIN
CHAPTER EIGHT: REGENERATIVE APPLICATIONS FOR BONES AND JOINTS: MATERIALS FOR BONE TISSUE REPAIR; INHERENT REGENERATION OF BONE; OVERALL SIZE OF BONE GRAFT BUSINESS; BONE GRAFT SUBSTITUTES; ALLOGRAFT TISSUE; OTHER OSTEOCONDUCTIVE BONE GRAFT SUBSTITUTES; HYDROGELS AND REGENERATION; COMPOSITION AND METHOD FOR SELF-ASSEMBLY AND MINERALIZATION OF PEPTIDE AMPHIPHILES; CHONDROITINASE ABC I POLYNUCLEOTIDES; Abstract; TRANSDISCAL ADMINISTRATION OF CYCLINE COMPOUNDS; Abstract; COMPOSITION AND METHOD FOR PREPARING BIOCOMPATIBLE SURFACES; Abstract; SPINAL MOBILITY PRESERVATION APPARATUS HAVING AN EXPANDABLE MEMBRANE; Abstract; MAJOR DISEASES AND CONDITIONS AFFECTING BONES; OSTEOPOROSIS; Currently Available Products to Treat Osteoporosis; Bisphosphonates; Fosamax; Boniva; Hormones; Evista; Forteo; Miacalcin; STEROIDS AND OSTEOPOROSIS; Glucocorticoids; THE MARKET FOR PRODUCTS TO TREAT OSTEOPOROSIS.; PAGET’S DISEASE; DRUGS CURRENTLY AVAILABLE TO TREAT PAGET’S DISEASE; Actonel; Aredia; Skelid; Zometa; THE MARKET FOR PRODUCTS TO TREAT PAGET’S DISEASE; INJURIES AND DEGENERATIVE CONDITIONS; HIP FRACTURES; TRADITIONAL TREATMENTS FOR BONE AND JOINT DISORDERS; MARKET LEADERS; JOINT-REPLACEMENT SURGERY; KNEE REPLACEMENTS; NATURAL THERAPEUTIC TREATMENTS FOR ARTHRITIS; IMAGING AND REGENERATION
CHAPTER NINE: ELECTRICAL BONE GROWTH STIMULATOR MARKET: OVERVIEW; SCIENTIFIC BASIS; ULTRASONIC OSTEOGENESIS STIMULATORS FOR BONE HEALING; MARKETERS OF INVASIVE AND NONINVASIVE ELECTRICAL BONE GROWTH STIMULATORS; BIOMET; ORTHOFIX; DJO, INC.; SMITH & NEPHEW; MARKET SIZE
CHAPTER TEN: ORTHOPEDICS—FDA CLEARANCES AND NEW PRODUCT DEVELOPMENT: SUPPLIERS OF REGENERATIVE BONE AND JOINT PRODUCTS
CHAPTER ELEVEN: MARKET FOR TISSUE ENGINEERING PRODUCTS: TISSUE ENGINEERING AND CELL THERAPY; RESEARCH INITIATIVES
CHAPTER TWELVE: REGENERATIVE CONCEPTS AND PRODUCTS IN DENTISTRY: OVERVIEW; INDICATIONS AND HISTORY; CHARACTERTISTICS AND MATERIALS; BARRIER MEMBRANES; NON-RESORBABLE; RESORBABLE; COLLAGEN RESORBABLE MEMBRANES; SYNTHETIC RESORBABLE MEMBRANES
CHAPTER THIRTEEN: SKIN TECHNOLOGIES: SKIN-LIKE TISSUE DEVELOPED FROM HUMAN EMBRYONIC STEM CELLS
CHAPTER FOURTEEN: NEUROLOGICAL APPLICATIONS IN REGENERATIVE MEDICINE: OVERVIEW; NEURODEGENERATIVE DISEASES; CURRENT CONVENTIONAL THERAPIES FOR THE TREATMENT OF NEURODEGENERATIVE DISEASE SYMPTOMS; SPINAL CORD INJURY, NEURODEGENERATIVE DISEASES, AND REGENERATIVE POTENTIAL; UNIVERSITY OF SOUTHERN CALIFORNIA (USC)
CHAPTER FIFTEEN: REGENERATIVE MEDICINE AND APPLICATIONS IN CARDIAC CARE: OVERVIEW; STEM CELLS FOR THE FUTURE TREATMENT OF HEART DISEASE; PARTICULAR R&D PRIORITIES; STEM CELLS AND BIOLOGICAL PACEMAKERS; HEART PROGENITOR CELLS DEVELOPED FROM EMBRYONIC STEM CELLS; OTHER CURRENT REGENERATIVE MEDICINE AS IT RELATES TO THE HEART
CHAPTER SIXTEEN: REGENERATIVE MEDICINE AND DIABETES: BACKGROUND; POSSIBLE APPLICATIONS FOR REGENERATIVE MEDICINE
CHAPTER SEVENTEEN: FDA APPROVED CLINICAL TRIALS INVOLVING REGENERATIVE MEDICINE: CURRENT STATUS OF THE REGENERATIVE MEDICINE BUSINESS; REGULATORY ENVIRONMENT; STATUS OF RESEARCH AND CLINICAL TRIALS; ANALYSIS OF CLINICAL TRIALS
CHAPTER EIGHTEEN: OVERSEAS ACTIVITIES: DOMESTIC VERSUS OVERSEAS REGENERATIVE MEDICINE COMPANIES; JAPAN; EUROPE; AUSTRALIA AND CHINA
CHAPTER NINETEEN: PATENT ANALYSIS: ANALYSIS; TISSUE ENGINEERING PATENTS; GEOGRAPHIC DISTRIBUTION; RECENT PATENTS; DIRECT DIFFERENTIATION METHOD FOR MAKING CARDIOMYOCYTES FROM HUMAN EMBRYONIC STEM CELLS; Abstract; METHOD FOR PREPARING NOVEL TRANSCRIPTION FACTORS AND USE; Abstract; ENDODERM CELLS FROM HUMAN EMBRYONIC STEM CELLS; Abstract; GENES WITH ES CELL-SPECIFIC EXPRESSION; Abstract; MARKER SYSTEM FOR PREPARING AND CHARACTERIZING HIGH-QUALITY HUMAN EMBRYONIC STEM CELLS; Abstract
CHAPTER TWENTY: COMPANY PROFILES: AASTROM BIOSCIENCES, INC.; ADVANCED BIOHEALING, INC.; ADVANCED CELL TECHNOLOGY, INC; AESCULAP, INC.; ALDAGEN, INC.; ALPHATEC SPINE, INC.; ANGIOTECH PHARMACEUTICALS, INC.; ARTERIOCYTE MEDICAL SYSTEMS, INC.; ARTHREX, INC.; ARTHROCARE CORPORATION; BIOMET, INC.; BIOMIMETIC THERAPEUTICS, INC.; BIOTISSUE TECHNOLOGIES GMBH; CAPSTONE THERAPEUTICS; CENTERPULSE ORTHOPAEDICS, INC.; CERAPEDICS, INC.; CITAGENIX, INC.; CONMED CORPORATION; CROSSCART INC.; CRYOLIFE, INC.; CURIS; CYTORI THERAPEUTICS, INC.; DEPUY ORTHOPAEDICS, INC. (UNIT OF THE DEPUY COMPANIES); DJO SURGICAL; ESBATECH AG; ETEX CORPORATION; EXACTECH, INC.; FATE THERAPEUTICS, INC.; GARNET BIOTHERAPEUTICS; GENZYME BIOSURGERY; GERON CORPORATION; INTEGRA LIFESCIENCES HOLDING CORP.; ISOTIS ORTHOBIOLOGICS, INC. (INTEGRA ORTHOBIOLOGICS); INTERNATIONAL STEM CELL; INTERPORE CROSS INTERNATIONAL; ISTO TECHNOLOGIES, INC.; KENSEY NASH CORPORATION; LIFECELL (A SUBSIDIARY OF KINETIC CONCEPTS, INC.); MCEWEN CENTRE FOR REGENERATIVE MEDICINE; MCGOWAN INSTITUTE FOR REGENERATIVE MEDICINE; MEDTRONIC, INC.; MESOBLAST, LIMITED; NATIONAL CENTER FOR REGENERATIVE MEDICINE; NATIONAL TISSUE ENGINEERING CENTER (NTEC); NEURALSTEM; NOVABONE PRODUCTS, LLC; NOVARTIS CORPORATION; NOVOCELL, INC.; OPEXA THERAPEUTICS; ORGANOGENESIS INC.; ORTHOFIX INTERNATIONAL N.V.; ORTHOPEUTICS, L.P.; ORTHOVITA, INC.; OSIRIS THERAPEUTICS, INC.; OSTEOTECH, INC.; PFIZER, INC.; PLURISTEM THERAPEUTICS; REGEN BIOLOGICS, INC.; RENEURON; RTI BIOLOGICS, INC.; SCIL TECHNOLOGY GMBH; SMITH AND NEPHEW; STEMCELLS, INC.; STEMCOR SYSTEMS, INC.; STRAUMANN USA LLC; STRYKER CORP.; SYNTHES, INC.; TENGION; TEPHA; THERMOGENESIS CORP.; TIGENIX N.V.; UCB S.A. (HEADQUARTERS); WAKE FOREST INSTITUTE FOR REGENERATIVE MEDICINE; WRIGHT MEDICAL GROUP, INC.; ZIMMER HOLDINGS, INC.; OTHER ORGANIZATIONS INVOLVED IN REGENRERATIVE MEDICINE R&D; ACADEMIC INSTITUTIONS; U.S. GOVERNMENT; OTHER SOCIETIES AND ORGANIZATIONS
CHAPTER TWENTY-ONE: GLOSSARY OF KEY TERMS IN REGENERATIVE MEDICINE BUSINESS: GLOSSARY OF KEY TERMS
LIST OF TABLES: SUMMARY TABLE U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, THROUGH 2014 ($ MILLIONS); TABLE 1 FUNCTIONAL ACTIVITIES WITH REGENERATIVE MEDICINE SECTOR; TABLE 2 PRINCIPAL REGENERATIVE MEDICINE BUSINESS R&D FOCUSES; TABLE 3 20-YEAR PLANNING HORIZON FOR REGENERATIVE MEDICINE BUSINESS: LIKELY DEVELOPMENTS, 2015-2030; TABLE 4 PRINCIPLE RESEARCH PROJECTS OF CIMIT IN THE TISSUE-ENGINEERING AND BIOMATERIALS FIELDS, 2008-2010; TABLE 5 COMMERCIAL SUPPLIERS OF BIOREACTORS FOR USE IN REGENERATIVE MEDICINE; TABLE 6 BONE MORPHOGENETIC PROTEINS; TABLE 7 U.S. MARKET FOR TISSUE-ENGINEERED CARTILAGE PRODUCTS, THROUGH 2014 ($ MILLIONS); TABLE 8 FEDERAL FUNDING FOR STEM CELL RESEARCH, THROUGH 2008 ($ MILLIONS); TABLE 9 STATE LEVEL PROGRAMS FOCUSED ON STEM CELL RESEARCH; TABLE 10 CHARACTERISTICS OF IDEAL BONE GRAFT MATERIAL; TABLE 11 U.S. BONE GRAFT PROCEDURE VOLUMES BY APPLICATION, THROUGH 2014; TABLE 12 U.S. BONE GRAFT PROCEDURE VOLUMES BY TYPE OF GRAFT, THROUGH 2014; TABLE 13 BONE GRAFT MATERIALS; TABLE 14 SUBSTITUTE BONE GRAFTS; TABLE 15 SELECTED DBM PRODUCTS AND PERCENTAGE OF DEMINERALIZED BONE MATRIX; TABLE 16 U.S. MARKET FOR PRECISION-MACHINED ALLOGRAFTS, THROUGH 2014 ($ MILLIONS); TABLE 17 WORLDWIDE MARKET FOR BONE REPLACEMENT PRODUCTS, THROUGH 2014 ($ MILLIONS); TABLE 18 U.S. MARKET FOR BONE-REPLACEMENT PRODUCTS, THROUGH 2014 ($ MILLIONS); TABLE 19 DRUGS USED TO TREAT OSTEOPOROSIS; TABLE 20 WORLDWIDE MARKET FOR DRUGS TO TREAT OSTEOPOROSIS, THROUGH 2014 ($ MILLIONS); TABLE 21 WORLDWIDE MARKET FOR DRUGS TO TREAT PAGET’S DISEASE, THROUGH 2014 ($ MILLIONS); TABLE 22 WORLDWIDE HIP FRACTURE VOLUMES, THROUGH 2014; TABLE 23 U.S. HIP FRACTURE VOLUMES, THROUGH 2014; TABLE 24 U.S. MARKET SHARES FOR MUSCULOSKELETAL PRODUCTS, 2008 (%); TABLE 25 U.S. RECONSTRUCTIVE DEVICE MARKET, 2008 (%); TABLE 26 HIP REPLACEMENT PROCEDURE VOLUMES, U.S., THROUGH 2014; TABLE 27 HISTORICAL RATES OF HIP REPLACEMEN IN SIX MAJOR STATES, 2001; TABLE 28 WORLDWIDE HIP REPLACEMENT MARKET, THROUGH 2014 ($ MILLIONS); TABLE 29 U.S. HIP REPLACEMENT MARKET, THROUGH 2014 ($ MILLIONS); TABLE 30 WORLDWIDE KNEE-REPLACEMENT PROCEDURE VOLUMES, THROUGH 2014; TABLE 31 U.S. KNEE REPLACEMENT PROCEDURE VOLUMES, THROUGH 2014; TABLE 32 WORLDWIDE KNEE REPLACEMENT MARKET, THROUGH 2014 ($ MILLIONS); TABLE 33 U.S. KNEE REPLACEMENT MARKET, THROUGH 2014 ($ MILLIONS); TABLE 34 U.S. MARKET FOR UNICONDYLAR KNEE REPLACEMENT, THROUGH 2014 ($ MILLIONS); TABLE 35 WORLDWIDE MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS, THROUGH 2014 ($ MILLIONS); TABLE 36 U.S. MARKET FOR NONINVASIVE BONE GROWTH STIMULATORS, THROUGH 2007 ($ MILLIONS); TABLE 37 RECENTLY APPROVED ORTHOPEDIC BONE AND JOINT DEVICES BY PRODUCT, COMPANY, AND APPROVAL DATE, 2008-2009; TABLE 38 SALES OF ENGINEERED SKIN GRAFTS AND REPLACEMENTS, THROUGH 2014 ($ MILLIONS); TABLE 39 REGENERATIVE MEDICINE CLINICAL TRIALS BY MAJOR CATEGORY; TABLE 40 CURRENT CLINICAL TRIALS IN THE FIELD OF REGENERATIVE MEDICINE STATUS, CONDITIONS, INTERVENTION, AND SPONSOR; TABLE 41 MOST FREQUENTLY CITED PATENT ASSIGNEES IN TISSUE ENGINEERING FIELD; TABLE 42 WORLD DISTRIBUTION OF REGENERATIVE MEDICINE PATENTS ISSUED, 1985-2009 (%); TABLE 43 PUBLICALLY TRADED COMPANIES IN THE REGENERATIVE MEDICINE INDUSTRY, AS OF JULY 1, 2009
LIST OF FIGURES: SUMMARY FIGURE U.S. MARKET FOR REGENERATIVE MEDICINE PRODUCTS USED IN BONE AND JOINT APPLICATIONS, 2007-2014 ($ MILLIONS); FIGURE 1 U.S. MARKET FOR PRECISION-MACHINED ALLOGRAFTS, 2007-2014 ($ MILLIONS); FIGURE 2 WORLDWIDE MARKET FOR BONE REPLACEMENT PRODUCTS, 2007-2014 ($ MILLIONS); FIGURE 3 U.S. MARKET FOR BONE-REPLACEMENT PRODUCTS, 2007-2014 ($ MILLIONS); FIGURE 4 WORLDWIDE MARKET FOR DRUGS TO TREAT OSTEOPOROSIS, 2007-2014 ($ MILLIONS); FIGURE 5 WORLDWIDE MARKET FOR DRUGS TO TREAT PAGET’S DISEASE, 2007-2014 ($ MILLIONS); FIGURE 6 WORLDWIDE HIP REPLACEMENT MARKET, 2007-2014 ($ MILLIONS); FIGURE 7 U.S. HIP REPLACEMENT MARKET, 2007-2014 ($ MILLIONS); FIGURE 8 WORLDWIDE KNEE REPLACEMENT MARKET, 2007-2014 ($ MILLIONS); FIGURE 9 U.S. KNEE REPLACEMENT MARKET, 2007-2014 ($ MILLIONS); FIGURE 10 U.S. MARKET FOR UNICONDYLAR KNEE REPLACEMENT, 2007-2014 ($ MILLIONS)

Regenerative Medicines: Bone and Joint Applications

Share this report

Other tasks

Research Assistance

Related Markets

Orthopedics Reports

Free Alert Me service